Status and phase
Conditions
Treatments
About
To evaluate effect of slow-release melatonin (Circadin) on REM sleep behavior disorder.
Full description
Investigators planned to administer low (2mg) and high (6mg) dose slow-release melatonin and the placebo for 4 weeks and evaluate Clinical Global Impression scale, RBD questionnaire, PSQI, Epworth sleepiness scale, and quality of life questionnaire (SF-36v2) before and after the treatment along with possible side effects and drug compliance.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 3 patient groups, including a placebo group
There are currently no registered sites for this trial.
Central trial contact
Ki-Young Jung, M.D. Ph.D.; Jung-Ick Byun, M.D.
Start date
Jan 01, 2016 • 9 years ago
End date
Dec 31, 2017 • 7 years ago
Today
Jan 22, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal